Literature DB >> 24713990

Oncofetal protein IMP3, a new cancer biomarker.

Yuna Gong1, Bruce A Woda, Zhong Jiang.   

Abstract

IMP3 is a member of a family of RNA-binding proteins that consists of IMP1, IMP2 and IMP3. These proteins contain 2 RNA recognition motifs and 4 K-homology domains that allow them to bind RNAs strongly and specifically. IMP3 is an oncofetal protein involved in embryogenesis and its expression is associated with a number of malignant neoplasms. IMP3 is associated with aggressive and advanced cancers and is specifically expressed in malignant tumors but is not found in adjacent benign tissues. Moreover, in vitro studies have shown that IMP3 promotes tumor cell proliferation, adhesion, and invasion. This review focuses on the studies of IMP3 expression in different cancers and emphasizes the potential utility of IMP3 in routine surgical pathology practice. We also discuss IMP3 as a prognostic biomarker for cancer patients' outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24713990     DOI: 10.1097/PAP.0000000000000021

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  17 in total

1.  IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage.

Authors:  Qingzhu Wei; Xiaoping Huang; Bo Fu; Jianghuan Liu; Ling Zhong; Qiao Yang; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 2.  Control of cell migration through mRNA localization and local translation.

Authors:  Guoning Liao; Lisa Mingle; Livingston Van De Water; Gang Liu
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-09-28       Impact factor: 9.957

3.  IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.

Authors:  Emanuel Adelino M Damasceno; Fabiana Pirani Carneiro; Albino Verçosa de Magalhães; Marcos de Vasconcelos Carneiro; Gustavo Henrique Soares Takano; Leonora Maciel de Sousa Vianna; Heinrich Bender Kohnert Seidler; Tercia Maria Mendes Lousa de Castro; Maria Imaculada Muniz-Junqueira; Rivadávio Fernandes Batista Amorim; Vânia Maria Moraes Ferreira; Andrea Barreto Motoyama
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-17       Impact factor: 4.553

4.  Gallbladder Cancer with Biliary Intraepithelial Neoplasia Complicated by Pancreaticobiliary Maljunction: A Case Report.

Authors:  Ken Sugezawa; Yoshiyuki Murawaki; Teruhisa Sakamoto; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2022-01-21       Impact factor: 1.641

5.  IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.

Authors:  Jinhai Yan; Qingzhu Wei; Wenjing Jian; Bo Qiu; Jing Wen; Jianghuan Liu; Bo Fu; Xinhua Zhou; Tong Zhao
Journal:  Lung       Date:  2015-11-25       Impact factor: 2.584

6.  The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas.

Authors:  Alessandro Del Gobbo; Valentina Vaira; Lucia Ferrari; Carlo Patriarca; Andrea Di Cristofori; Dario Ricca; Manuela Caroli; Paolo Rampini; Silvano Bosari; Stefano Ferrero
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

7.  Prognostic value of high IMP3 expression in solid tumors: a meta-analysis.

Authors:  Luyao Chen; Yongpeng Xie; Xintao Li; Liangyou Gu; Yu Gao; Lu Tang; Jianwen Chen; Xu Zhang
Journal:  Onco Targets Ther       Date:  2017-06-06       Impact factor: 4.147

8.  Analysis of IMP3 expression in primary tumor and stromal cells in patients with colorectal cancer.

Authors:  Xiaoping Huang; Qingzhu Wei; Jianghuan Liu; Hongling Niu; Gang Xiao; Lixin Liu
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

9.  Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Authors:  Cristina Rius; Meriem Attaf; Katie Tungatt; Valentina Bianchi; Mateusz Legut; Amandine Bovay; Marco Donia; Per Thor Straten; Mark Peakman; Inge Marie Svane; Sascha Ott; Tom Connor; Barbara Szomolay; Garry Dolton; Andrew K Sewell
Journal:  J Immunol       Date:  2018-02-26       Impact factor: 5.422

Review 10.  Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations.

Authors:  Ulf Landegren; Maria Hammond
Journal:  Mol Oncol       Date:  2020-11-17       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.